PD-L1 inhibitor
Showing 1 - 25 of >10,000
Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)
Completed
- Advanced Solid Tumor
- Inosine 0.2g orally 3 times/day
- PD-1/PD-L1 inhibitor ,chemotherapy/targeting
-
Beijing, Beijing, ChinaQin li
Mar 30, 2023
Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)
Not yet recruiting
- Lung Cancer
- Centipeda minima+PD-1/PD-L1 inhibitor
- PD-1/PD-L1 inhibitor
- (no location specified)
Feb 17, 2023
Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)
Not yet recruiting
- Metastatic Microsatellite-stable Colorectal Cancer
- (no location specified)
Sep 1, 2023
Efficacy, Safety Trial (PD-L1 inhibitor)
Not yet recruiting
- Efficacy
- Safety
- PD-L1 inhibitor
- (no location specified)
Apr 6, 2022
NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Carcinoma Breast
- Vinorelbine
- +4 more
-
Suzhou, ChinaSecond Affiliated Hospital of Soochow University
Oct 29, 2022
Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)
Recruiting
- Advanced Solid Tumor
- Refractory Tumor
- Thymalfasin
- +3 more
-
Suzhou, ChinaThe Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023
Transitional Cell Tumor, Hepatoblastoma, Liver Cancer Trial in Shanghai (PD-1 inhibitor)
Not yet recruiting
- Transitional Cell Tumor
- +4 more
- PD-1 inhibitor
-
Shanghai, ChinaRen Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
Apr 3, 2022
Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage
Recruiting
- Advanced Solid Tumor
- Refractory Tumor
- Radiotherapy
- +4 more
-
Suzhou, ChinaThe Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023
Malignant Pleural Mesothelioma Trial in Edegem, Ghent, Sint-Niklaas (Dendritic cell vaccination, Atezolizumab,
Not yet recruiting
- Malignant Pleural Mesothelioma
- Dendritic cell vaccination
- +2 more
-
Edegem, Antwerp, Belgium
- +2 more
Feb 28, 2023
PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on
Recruiting
- Hepatocellular Carcinoma
- Acute Rejection
-
Beijing, Beijing, ChinaBeijing Tsinghua Changgung Hospital
Jun 6, 2022
Metastasis, Solid Tumor Trial (Peptide Alarm Therapy (PAT))
Not yet recruiting
- Metastasis
- Solid Tumor
- Peptide Alarm Therapy (PAT)
- (no location specified)
Nov 2, 2022
Esophageal Squamous Cell Carcinoma Trial (Anlotinib+TQB2450)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- (no location specified)
Feb 8, 2022
Metastatic Cancer, Urothelial Carcinoma Trial (avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin)
Not yet recruiting
- Metastatic Cancer
- Urothelial Carcinoma
- avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
- (no location specified)
Dec 19, 2022
Metastatic Urothelial Cancer Trial in China (Enfortumab vedotin)
Active, not recruiting
- Metastatic Urothelial Cancer
- Enfortumab vedotin
-
Beijing, China
- +7 more
Aug 23, 2022
Non Small Cell Lung Cancer Metastatic Trial (Pembrolizumab in Combination with Plinabulin and Docetaxel)
Not yet recruiting
- Non Small Cell Lung Cancer Metastatic
- Pembrolizumab in Combination with Plinabulin and Docetaxel
- (no location specified)
Oct 28, 2022
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors Trial in Baltimore (Nivolumab, Relatlimab)
Recruiting
- Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
- MSI-H Tumors
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Mar 14, 2022
Chronic Hepatitis b Trial in Auckland (AB-101, Placebo, Nucleos(t)ide Analogue)
Not yet recruiting
- Chronic Hepatitis b
- AB-101
- +2 more
-
Auckland, New ZealandNew Zealand Clinical Research Auckland
Jul 26, 2023
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 Trial (Nivolumab,
Withdrawn
- Lung Non-Small Cell Carcinoma
- +12 more
- Nivolumab
- Sapanisertib
- (no location specified)
May 24, 2022
Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)
Not yet recruiting
- Metastatic Pancreatic Cancer
- Durvalumab
- Rintatolimod
-
Rotterdam, Zuid-Holland, NetherlandsErasmus MC
Jun 23, 2023
Advanced Solid Cancers, Advanced Solid Cancers Refractory to PD-1 Trial in United States (AGEN1884)
Completed
- Advanced Solid Cancers
- Advanced Solid Cancers Refractory to PD-1
-
Duarte, California
- +10 more
Apr 28, 2022
Solid Tumor, Lymphoma Trial in Beijing (HG146, PD-(L)1 antibody)
Recruiting
- Solid Tumor
- Lymphoma
- HG146
- PD-(L)1 antibody
-
Beijing, ChinaNational Cancer Center/Cancer Hospital
Mar 16, 2022
Solid Tumor, Adult Trial in Dallas (Isunakinra, PD-(L)1 Inhibitor)
Recruiting
- Solid Tumor, Adult
- Isunakinra
- PD-(L)1 Inhibitor
-
Dallas, TexasBaylor Charles A. Simmons Cancer Center
Jul 20, 2021
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh
Not yet recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +3 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 8, 2022
Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced
Recruiting
- Esophageal Neoplasms
- an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
-
Zhengzhou, Henan, ChinaThe First Affiliated Hospital of Zhengzhou University
Apr 21, 2022